

**Search Results - Record(s) 1 through 13 of 13 returned.**

---

- ☐ 1. 6143278. 23 Feb 98; 07 Nov 00. Topical application of opioid analgesic drugs such as morphine. Elkhoury; George F.. 424/45; 424/43 424/484 424/485 424/486 424/487 424/488 514/282 514/812 514/944 514/946 514/947 514/969. A61K009/12 A61K009/06 A61K031/485 .
- 
- ☐ 2. 6121329. 27 Aug 97; 19 Sep 00. Topical administration of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol. Fujii; Tsuneo, et al. 514/653; 424/400 424/427 424/443 424/45 514/885 514/886 514/912 514/946 514/947 514/966 514/969. A61K033/24 A01N059/16 .
- 
- ☐ 3. 6011022. 21 May 98; 04 Jan 00. Topical application of muscarinic analgesic drugs such as neostigmine. El Khoury; George F.. 514/78; 514/940 514/946 514/947 514/969. A61K031/66 .
- 
- ☐ 4. 6004579. 04 Sep 97; 21 Dec 99. Compositions which inhibit apoptosis, methods of making the compositions and uses thereof. Bathurst; Ian C., et al. 424/450; 424/401 435/1.1 435/1.2 514/75 514/78 514/844 514/863 514/880. A61K009/127 .
- 
- ☐ 5. 5981606. 05 Feb 98; 09 Nov 99. Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same. Martin; Alain. 514/724; 514/458 514/725 514/946 514/947. A61K031/045 A61K031/07 A61K031/355 .
- 
- ☐ 6. 5972911. 26 May 92; 26 Oct 99. Composition for the delivery of orally administered drugs and other substances. Yesair; David W.. 514/77; 514/558 514/560 514/946 514/947. A61K031/685 A61K031/20 .
- 
- ☐ 7. 5874479. 05 Feb 98; 23 Feb 99. Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same. Martin; Alain. 514/724; 514/458 514/725 514/946 514/947. A61K031/045 A61K031/07 A61K031/355 .
- 
- ☐ 8. 5116606. 24 May 90; 26 May 92. Skin treatment method and solution. Alt; John P.. 514/458; 424/680 514/563 514/642 514/859 514/864 514/880 514/881. A61K007/06 A61K007/075 .
- 
- ☐ 9. 5057497. 13 Jul 89; 15 Oct 91. Oral method for the maintenance of healthy gingival tissues using TRF. Calam; Henry D., et al. 514/21; 424/49 424/50 424/559 424/562 514/12 514/900 514/901 514/902 514/946 514/947 514/969. A61K007/16 A61K035/54 A61K037/22 .
-

10. 4976967. 21 Nov 88; 11 Dec 90. Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts. McClelland; Gregory A., et al. 424/473; 424/457 424/474 514/946. A61R009/24 .

---

11. 4973579. 16 Feb 89; 27 Nov 90. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts. Alexander; Jose, et al. 514/49; 514/263.34 514/43 514/45 514/46 514/788 514/946. A61K031/70 A61K031/52 A61K047/00 .

---

12. 4822773. 20 Dec 87; 18 Apr 89. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts. Alexander; Jose, et al. 514/3; 514/11 514/15 514/2 514/561 514/565 514/567 514/946 514/947 930/21 930/270. A61K037/26 A61K037/00 A61K031/195 .

---

13. 4729989. 28 Jun 85; 08 Mar 88. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts. Alexander; Jose, et al. 514/192; 514/193 514/194 514/195 514/196 514/197 514/198 514/199 514/200 514/201 514/202 514/203 514/205 514/206 514/207 514/208 514/209 514/4 514/946 514/947 930/21 930/270. A61K031/43 A61K031/545 .

# Structure Search

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Documents and Settings\sgraham\Desktop\STN structures\09974519.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:16:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 537 TO ITERATE

100.0% PROCESSED 537 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 9350 TO 12130

PROJECTED ANSWERS: 2 TO 124

L2 (2) SEA SSS SAM L1

=> d l2 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN

RN 933064-08-5 REGISTRY

ED Entered STN: 29 Apr 2007

CN 2H-Tetrazolium, 3-(1-naphthalenyl)-2,5-diphenyl-, chloride (1:1), mixt.  
with 2-[[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium  
inner salt (CA INDEX NAME)

OTHER NAMES:

CN Miltefosine-Tetrazolium violet mixture

MF C23 H17 N4 . C21 H46 N O4 P . Cl

CI MXS


SR CA

LC STN Files: CA, CAPLUS

CM 1

CRN 58066-85-6


CMF C21 H46 N O4 P



CM 2

CRN 1719-71-7 (134102-55-9)

CMF C23 H17 N4 . Cl



● Cl<sup>-</sup>

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN

RN 80078-44-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN Ethanaminium, 2-[[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, hydroxide (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Choline phosphate, hexadecyl ester, hydroxide (6CI)

MF C21 H47 N O4 P . H O

LC STN Files: CA, CAOLD, CAPLUS, IMSPATENTS, IMSRESEARCH, TOXCENTER

CRN (82721-45-7)



● OH<sup>-</sup>

6 REFERENCES IN FILE CA (1907 TO DATE)

6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s ll sss full

FULL SEARCH INITIATED 10:17:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10692 TO ITERATE


100.0% PROCESSED 10692 ITERATIONS  
SEARCH TIME: 00.00.01

36 ANSWERS

L3 (36) SEA SSS FUL L1

=> d scan 13


L3 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Ethanaminium, 2-[[[eicosyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-,  
hydroxide (9CI)  
MF C25 H55 N O4 P . H O



● OH<sup>-</sup>

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Ethanaminium, 2-[[[hexadecyloxy)hydroxyphosphinyl]oxy]-N,N-dimethyl-N-(  
methyl-14C)-, inner salt (9CI)  
MF C21 H46 N O4 P



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> help roles

Super roles, available in all indexed documents in Cplus or CA from 1967 to the present, are also searchable in the REGISTRY and ZREGISTRY files. Roles are CAS indexing terms consisting of codes that describe the new or novel information reported about a specific substance or a non-specific derivative of a specific substance. Enter HELP ROLES at an arrow prompt in Cplus or CA for more information about CAS roles.

CAS super roles may be searched in the REGISTRY or ZREGISTRY file in the following search fields:

Search Field Name	Search Code	Display Code
Super roles for specific substances	/RL	RL
Super roles for non-specific derivatives	/RLD	RLD

Super roles for specific substances and non-specific derivatives	/RLS	RLS
Super roles for specific substances from patents	/RL.P	RL.P
Super roles for non-specific derivatives from patents	/RLD.P	RLD.P
Super roles for specific substances and non-specific derivatives from patents	/RLS.P	RLS
Super roles for specific substances from non-patent documents	/RL.NP	RL.NP
Super roles for non-specific derivatives from non-patent documents	/RLD.NP	RLD.NP
Super roles for specific substances and non-specific derivatives from non-patent documents	/RLS.NP	RLS

List of CAS Super Roles searchable in REGISTRY/ZREGISTRY

Code Phrase

ANST	Analytical Study
BIOL	Biological Study
CMBI	Combinatorial Study
FORM	Formation, Nonpreparative
MSC	Miscellaneous
OCCU	Occurrence
PREP	Preparation
PROC	Process
PRP	Properties
RACT	Reactant or Reagent
USES	Uses

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

181.85

184.58

FILE 'CAPLUS' ENTERED AT 10:23:39 ON 22 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2007 VOL 147 ISS 9

FILE LAST UPDATED: 21 Aug 2007 (20070821/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13/uses

592 L3  
6658737 USES/RL  
L4 328 L3/USES  
(L3 (L) USES/RL)

=> d scan 14

L4 328 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN  
CC 1-6 (Pharmacology)  
TI Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumor cells  
ST hexadecylphosphocholine antitumor phospholipid cholesterol membrane apoptosis tumor  
IT Esterification  
(cholesterol; hexadecylphosphocholine disrupts cholesterol homeostasis and induces accumulation of free cholesterol in HepG2 tumor cells)  
IT Antitumor agents  
Apoptosis  
Cell membrane  
DNA fragmentation  
Human  
Neoplasm  
(hexadecylphosphocholine disrupts cholesterol homeostasis and induces accumulation of free cholesterol in HepG2 tumor cells)  
IT Phospholipids, biological studies  
Sphingomyelins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hexadecylphosphocholine disrupts cholesterol homeostasis and induces accumulation of free cholesterol in HepG2 tumor cells)  
IT 57-88-5, Cholesterol, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(esterification; hexadecylphosphocholine disrupts cholesterol homeostasis and induces accumulation of free cholesterol in HepG2 tumor cells)  
IT 9027-63-8, Acyl CoA cholesterol acyltransferase 169592-56-7, Caspase-3  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hexadecylphosphocholine disrupts cholesterol homeostasis and induces accumulation of free cholesterol in HepG2 tumor cells)  
IT 58066-85-6, Hexadecylphosphocholine  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hexadecylphosphocholine disrupts cholesterol homeostasis and induces accumulation of free cholesterol in HepG2 tumor cells)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 328 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN  
CC 10-5 (Microbial, Algal, and Fungal Biochemistry)  
TI Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs  
ST leishmanicide choline phosphocholine analog; choline transport inhibitor leishmanicide activity promastigote  
IT Leishmania major  
Protonmotive force  
(choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs)  
IT Protozoacides  
(leishmanicides; choline transport-inhibiting choline and phosphocholine analogs in relation to)  
IT Development, microbial  
(promastigote; choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs)  
IT Biological transport  
(uptake, carrier-mediated; choline transport in Leishmania major

promastigotes and its inhibition by choline and phosphocholine analogs)

IT 62-49-7, Choline  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (choline transport in Leishmania major promastigotes and its inhibition  
 by choline and phosphocholine analogs)

IT 56-54-2, Quinidine 57-09-0, CTAB 83-89-6, Quinacrine 130-95-0,  
 Quinine 312-45-8, Hemicholinium-3 541-22-0, Decamethonium bromide  
 1119-94-4, DTAB 1120-02-1, OTAB 58066-85-6, Miltefosine  
 70641-51-9, Edelfosine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (choline transport in Leishmania major promastigotes and its inhibition  
 by choline and phosphocholine analogs)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 14 and py<=2000  
 20934507 PY<=2000

(L5) (118) L4 AND PY<=2000

=> s 15 and (phospholipase C or lecithinase or phosphocoline or  
 phosphatidylinositol) and (epithili? or interstitial or intercellula? or  
 paracellula? or permeab?)

46572 PHOSPHOLIPASE  
 4940 PHOSPHOLIPASES  
 47631 PHOSPHOLIPASE  
 (PHOSPHOLIPASE OR PHOSPHOLIPASES)

3678349 C

20707 PHOSPHOLIPASE C  
 (PHOSPHOLIPASE (W) C)

969 LECITHINASE  
 58 LECITHINASES  
 988 LECITHINASE  
 (LECITHINASE OR LECITHINASES)

15 PHOSPHOCOLINE  
 1 PHOSPHOCOLINES  
 16 PHOSPHOCOLINE  
 (PHOSPHOCOLINE OR PHOSPHOCOLINES)

35541 PHOSPHATIDYLINOSITOL  
 15708 PHOSPHATIDYLINOSITOLS  
 42635 PHOSPHATIDYLINOSITOL  
 (PHOSPHATIDYLINOSITOL OR PHOSPHATIDYLINOSITOLS)

24 EPITHILI?  
 66467 INTERSTITIAL  
 11518 INTERSTITIALS  
 71082 INTERSTITIAL  
 (INTERSTITIAL OR INTERSTITIALS)

34655 INTERCELLULA?  
 2811 PARACELLULA?

238218 PERMEAB?

L6 (10) L5 AND (PHOSPHOLIPASE C OR LECITHINASE OR PHOSPHOCOLINE OR PHOSP  
 HATIDYLINOSITOL) AND (EPITHILI? OR INTERSTITIAL OR INTERCELLULA?  
 OR PARACELLULA? OR PERMEAB?)

=> s 15 and (phospholipase C or lecithinase or phosphocoline or  
 phosphatidylinositol or epithili? or interstitial or intercellula? or paracellula?  
 or permeab?)

46572 PHOSPHOLIPASE  
 4940 PHOSPHOLIPASES  
 47631 PHOSPHOLIPASE  
 (PHOSPHOLIPASE OR PHOSPHOLIPASES)

3678349 C

20707 PHOSPHOLIPASE C  
 (PHOSPHOLIPASE (W) C)



969 LECITHINASE  
 58 LECITHINASES  
 988 LECITHINASE  
       (LECITHINASE OR LECITHINASES)  
 15 PHOSPHOCOLINE  
   1 PHOSPHOCOLINES  
 16 PHOSPHOCOLINE  
       (PHOSPHOCOLINE OR PHOSPHOCOLINES)  
 35541 PHOSPHATIDYLINOSITOL  
 15708 PHOSPHATIDYLINOSITOLS  
 42635 PHOSPHATIDYLINOSITOL  
       (PHOSPHATIDYLINOSITOL OR PHOSPHATIDYLINOSITOLS)  
   24 EPITHILI?  
 66467 INTERSTITIAL  
 11518 INTERSTITIALS  
 71082 INTERSTITIAL  
       (INTERSTITIAL OR INTERSTITIALS)  
 34655 INTERCELLULA?  
   2811 PARACELLULA?  
 238218 PERMEAB?  
 L7    11 L5 AND (PHOSPHOLIPASE C OR LECITHINASE OR PHOSPHOCOLINE OR PHOSP  
           HATIDYLINOSITOL OR EPITHILI? OR INTERSTITIAL OR INTERCELLULA?  
           OR PARACELLULA? OR PERMEAB?)

=> dscan 1-11  
 DSCAN IS NOT A RECOGNIZED COMMAND  
 The previous command name entered was not recognized by the system.  
 For a list of commands available to you in the current file, enter  
 "HELP COMMANDS" at an arrow prompt (=>).

=> dscan 17 1-11  
 DSCAN IS NOT A RECOGNIZED COMMAND  
 The previous command name entered was not recognized by the system.  
 For a list of commands available to you in the current file, enter  
 "HELP COMMANDS" at an arrow prompt (=>).

=> d scan 17 1-11  
 '1-11' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

L7    11 ANSWERS   CAPLUS   COPYRIGHT 2007 ACS on STN  
 CC    1-6 (Pharmacology)  
 TI    The interference effects of hexadecylphosphocholine on proliferation and  
       membrane phospholipid metabolism in human myeloid leukemia cell lines  
 ST    antitumor leukemia cell membrane phospholipid hexadecylphosphocholine  
 IT    Antitumor agents  
       (leukemia; membrane phospholipid metabolism effect on antiproliferative  
       sensitivity of leukemia cells to hexadecylphosphocholine)  
 IT    Cell membrane  
       (membrane phospholipid metabolism effect on antiproliferative sensitivity  
       of leukemia cells to hexadecylphosphocholine)  
 IT    Phosphatidylcholines, biological studies  
       Phosphatidylethanolamines, biological studies  
       Phosphatidylinositols  
       Phosphatidylserines  
       Phospholipids, biological studies  
 RL:   BPR (Biological process); BSU (Biological study, unclassified); BIOL  
       (Biological study); PROC (Process)  
       (membrane phospholipid metabolism effect on antiproliferative sensitivity  
       of leukemia cells to hexadecylphosphocholine)  
 IT    58066-85-6, Hexadecylphosphocholine  
 RL:   BAC (Biological activity or effector, except adverse); BSU (Biological  
       study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
       (membrane phospholipid metabolism effect on antiproliferative sensitivity